Our Commitment to Patients

Equillium is dedicated to finding new treatments to dramatically improve the lives of patients with diseases where treatment options are limited or not available. Our lead product candidate, itolizumab, has a novel mechanism that blocks key drivers of inflammation that lie at the root of many diseases.

Disease Areas

Link to: Graft-Versus-Host Disease

Graft-Versus-Host-Disease

Hematopoietic stem cell transplant (HSCT) provides a potentially curative option for some types of cancer, but it comes with the risk of GVHD. GVHD occurs when the transplanted immune system attacks the recipient’s body and is the leading cause of non-cancer death in stem cell transplant recipients.

Link to: Lupus Nephritis

Lupus Nephritis

Lupus nephritis is among the most serious complications of systemic lupus erythematosus (SLE), occurring in 30 – 60% of individuals with SLE. In lupus nephritis, the body’s own immune system attacks the kidneys, causing inflammation and significantly reducing kidney function over time.

Link to: Uncontrolled Moderate to Severe Asthma

Uncontrolled Moderate to Severe Asthma

Individuals with asthma live with constant airway inflammation. Certain environmental triggers, exercise or illness can cause even more swelling and constriction of the muscles around the airway, making it difficult to breath.